Equisights Research (“Equisights”) is a distinguished independent sell-side research firm that excels in delivering in-depth, objective analysis and strategic insights. Our research efforts are primarily centered on the U.S. markets, with a strong sectoral emphasis on Technology, Media, and Telecommunications (TMT), healthcare, consumer cyclicals & non-cyclicals, industrials, energy, and select financials. Equisights serves to several notable buy-side funds, RIAs, family offices, and over 1,000 institutional relationships, who take positions across our coverage universe and manage portfolios ranging from $100 million to $1 billion in assets.
Our comprehensive research framework involves an in-depth analysis of each company’s growth potential, financial health, management quality, industry position, risk factors, and valuation. Our recommendations and ratings process is based on gathering and interpreting data, drawing conclusions, and evaluating these factors to determine final ratings based on intrinsic value, expected growth, and risks. Equisights maintains its independence by not participating in public offerings, advising on mergers and acquisitions, brokering trades, making markets in stocks, or managing money.
RESEARCH FEED : OUR PERSPECTIVE
Targa Resources (TRGP): Turning Down Takeovers? A Bull’s Perspective on Their Focused Organic Expansion and Market Leverage!
According to Bloomberg, Targa Resources Corp. recently rejected informal takeover interest from larger competitor Williams Cos., signaling ongoing consolidation appetite in the pipeline sector. Targa viewed Williams’ approach as undervaluing its current market capitalization, reflecting the company’s strategic resistance to transactions perceived as misaligned with its valuation trajectory. Wi... Read MoreTarget Corporation (TGT): Traffic and Tech “Drive Up” Gains, But Does Discretionary Weakness Raise Longer-Term Questions!
Target’s Q2 fiscal 2024 results showcased solid top-line growth and operating margin improvement, with comparable store sales rising by 2% and operating margins expanding by 160 basis points to 6.4%. This performance drove a significant stock price increase. However, the results warrant a deeper analysis. While positive same-store sales reflect Target’s ability to recover from a challenging pe... Read MoreAtlassian Corporation (TEAM): Balancing Short-Term Slowdown with Long-Term 2027 Targets !
Atlassian reported strong Q4 results, with revenue growing 20% year-over-year to $1.132 billion, slightly exceeding guidance. Subscription revenue increased by 34% year-over-year to $1.069 billion, due to lower seat counts and late deal closures. Cloud revenue also grew 31% to $738 million, driven by migrations and upsell. Data center revenue grew 41%, matching guidance, while non-GAAP operating m... Read MoreSTERIS Plc (STE): Riding the Crest of Procedural Growth—Balancing Headwinds with Recurring Revenue and Margin Expansion !-
STERIS CEO Daniel Carestio emphasized strong procedural volume growth in the U.S., with high single-digit rebounds in the Rust Belt and robust demand across Sun Belt states. Europe lags behind by 6-9 months, but recovery signals are emerging. We believe STERIS is capitalizing on the shift from acute care hospitals to ASCs, driving demand for its sterilization equipment and consumables, further sol... Read MoreAltria (MO): Battling Illicit Market Pressures—Evaluating Key Cost & Profit Drivers Amid Challenging Market Dynamics
Altria's second-quarter 2024 results reveal a business navigating both pressures and opportunities. The company faces a continued decrease in cigarette volumes, exacerbated by macroeconomic challenges and the rise of illicit e-vapor products, which now account for more than 60% of the market. Nicotine pouches and alternative tobacco products are gaining traction, further intensifying competition. ... Read MoreLowe’s Companies, Inc (LOW): Flywheel Effect?—Pro-Growth Momentum and AI Investments Setting the Stage!
Lowe’s Q2 2024 results reflected the effects of weakened consumer spending, with same-store sales down 5.1% and a 5.5% decline in total revenue. However, professional sales rose in the mid-single digits, and online sales grew 2.9%, highlighting pockets of resilience. However, Pro sales and online growth provided resilience, showcasing the strength of Lowe’s Total Home strategy and omnichannel ... Read MoreIllinois Tool Works: Weathering the Storm—Margin Strength Holds, but Growth Still in the Balance- What Lies Ahead ?
Illinois Tool Works (ITW) faces headwinds tied to softening demand in short-cycle and CapEx-sensitive segments, particularly Welding, Test & Measurement, and Construction Products. Additionally, a 2% decline in automotive builds, compounded by foreign currency impacts and higher tax rates, has pressured EPS. Weakness in semiconductor and electronics markets has further weighed on results. Howe... Read MoreIllinois Tool Works: Weathering the Storm—Margin Strength Holds, but Growth Still in the Balance- What Lies Ahead ?
Illinois Tool Works (ITW) faces headwinds tied to softening demand in short-cycle and CapEx-sensitive segments, particularly Welding, Test & Measurement, and Construction Products. Additionally, a 2% decline in automotive builds, compounded by foreign currency impacts and higher tax rates, has pressured EPS. Weakness in semiconductor and electronics markets has further weighed on results. Howe... Read MoreThe Hershey Company (HSY): Leveraging Seasonal Demand with Ramped Up Innovation & Continued Investments
Hershey’s Q2 2024 results reflected mixed dynamics with headwinds. Revenue of $2.07B missed expectations by $246M, down 16.7% YoY and 36.2% sequentially, driven by an 8-9% impact from lower retail inventory levels and Halloween timing shifts. Net price realization improved 6-7% through targeted pricing actions, but elevated cocoa costs continued to pressure gross margins despite some temporary r... Read MoreEW: What Makes Edwards Lifesciences a Hot Acquisition Target—And What’s It Really Worth
Edwards Lifesciences’ Q2 2024 performance delivered mixed results, with revenue up 6.67% YoY to $1.63 billion, but missing expectations by $20.9 million. The company’s standout TMTT segment saw a 75% surge in sales, driven by strong adoption of the PASCAL and EVOQUE systems, positioning Edwards as a leader in the rapidly expanding mitral and tricuspid valve markets. However, the TAVR segment, ... Read More- GM expects 2025 earnings to be 'similar' to this year despite industry headwinds
- PepsiCo trims revenue outlook as North American snacking, key international markets lag
- Samsung posts disappointing third-quarter profit guidance as it grapples with AI chips
- Foxconn beats estimates with record third-quarter revenue on AI demand
- Rivian shares fall after EV maker slashes production forecast, misses Q3 delivery expectations
- Levi Strauss trims guidance as it weighs sale of Dockers business
- Solana cryptocurrency could rally 400% if Trump wins election, Standard Chartered says
- Stocks making the biggest moves midday: Nvidia, DocuSign, Alibaba, Las Vegas Sands and more
- Ray Dalio says investing in China is tricky as Beijing becomes less favorable toward capitalism
- Stocks making the biggest moves premarket: DocuSign, Wynn Resorts, Nvidia and more
- China state planner lays out further actions to boost economy but no new plans for major stimulus
- Crypto relationship scams pose 'catastrophic harm,' SEC official says. Here's how to avoid them
- India flags cricket rights concerns with Disney-Reliance $8.5 bln merger
- OPEC+ sticks to oil policy, repeats could pause Oct hike
- US, Vietnam discuss supplying Hanoi with C-130 military transport planes
- Bosch weighs offer for appliance maker Whirlpool
- Japan spot work startup Timee targets July listing
- Qatar sovereign fund agrees to buy 10% stake in China asset manager